A Phase 3, Multicenter, Randomized, Open-Label, Comparator-Controlled Study to Assess Safety and Tolerability of Weekly TV-1106 Compared to Daily rhGH (dGH) in Adults With Growth Hormone-Deficiency

Trial Profile

A Phase 3, Multicenter, Randomized, Open-Label, Comparator-Controlled Study to Assess Safety and Tolerability of Weekly TV-1106 Compared to Daily rhGH (dGH) in Adults With Growth Hormone-Deficiency

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Albusomatropin (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Registrational
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 26 Apr 2016 Status changed from active, no longer recruiting to discontinued due to a Business decision.
    • 02 Mar 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2016 as per ClinicalTrials.gov record.
    • 02 Mar 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top